D. Boral Capital Reiterates “Buy” Rating for GeoVax Labs (NASDAQ:GOVX)

D. Boral Capital restated their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a research report released on Thursday,Benzinga reports. They currently have a $18.00 price target on the stock.

GeoVax Labs Price Performance

NASDAQ GOVX opened at $0.95 on Thursday. The stock’s 50 day simple moving average is $1.45 and its 200-day simple moving average is $2.00. The company has a market cap of $13.15 million, a PE ratio of -0.17 and a beta of 3.70. GeoVax Labs has a 1-year low of $0.88 and a 1-year high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.49. The firm had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $2.38 million. On average, equities research analysts anticipate that GeoVax Labs will post -4.49 EPS for the current fiscal year.

Institutional Trading of GeoVax Labs

A number of hedge funds have recently bought and sold shares of GOVX. Geode Capital Management LLC boosted its holdings in shares of GeoVax Labs by 59.0% during the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock worth $223,000 after purchasing an additional 33,440 shares during the last quarter. Citadel Advisors LLC purchased a new position in GeoVax Labs during the fourth quarter worth approximately $104,000. Virtu Financial LLC purchased a new position in GeoVax Labs during the third quarter worth approximately $97,000. Finally, Northern Trust Corp acquired a new position in GeoVax Labs during the fourth quarter worth $29,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.